Hans J. Hammers

26.6k total citations · 3 hit papers
216 papers, 8.1k citations indexed

About

Hans J. Hammers is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Hans J. Hammers has authored 216 papers receiving a total of 8.1k indexed citations (citations by other indexed papers that have themselves been cited), including 174 papers in Pulmonary and Respiratory Medicine, 119 papers in Oncology and 72 papers in Cancer Research. Recurrent topics in Hans J. Hammers's work include Renal cell carcinoma treatment (157 papers), Cancer Immunotherapy and Biomarkers (86 papers) and Cancer Genomics and Diagnostics (57 papers). Hans J. Hammers is often cited by papers focused on Renal cell carcinoma treatment (157 papers), Cancer Immunotherapy and Biomarkers (86 papers) and Cancer Genomics and Diagnostics (57 papers). Hans J. Hammers collaborates with scholars based in United States, France and Canada. Hans J. Hammers's co-authors include Brian I. Rini, Роберто Пили, David F. McDermott, Elizabeth R. Plimack, Saby George, Robert J. Motzer, Michael A. Carducci, Ian M. Waxman, Martin H. Voss and Asim Amin and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Hans J. Hammers

201 papers receiving 8.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

2014 865 citations Robert J. Motzer, Brian I. Rini et al. Journal of Clinical Oncology profile →
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth

2008 520 citations Hans J. Hammers, Роберто Пили et al. profile →
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

2017 348 citations Hans J. Hammers, Elizabeth R. Plimack et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Hans J. Hammers

Since Specialization

Citations

This map shows the geographic impact of Hans J. Hammers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans J. Hammers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans J. Hammers more than expected).

Fields of papers citing papers by Hans J. Hammers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans J. Hammers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans J. Hammers. The network helps show where Hans J. Hammers may publish in the future.

Co-authorship network of co-authors of Hans J. Hammers

This figure shows the co-authorship network connecting the top 25 collaborators of Hans J. Hammers. A scholar is included among the top collaborators of Hans J. Hammers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans J. Hammers. Hans J. Hammers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Surgical Outcomes of Radical Nephrectomy and Inferior Vena Cava Thrombectomy Following Preoperative Systemic Immunotherapy: A Propensity Score Analysis 2025 ·Clinical Genitourinary Cancer ·(unknown), Raj Bhanvadia, Isamu Tachibana, (unknown), (unknown), (unknown), Solomon L. Woldu, Kris E. Gaston, (unknown), Hans J. Hammers, Suzanne Cole, Tian Zhang, Karim Bensalah, Yair Lotan, Vitaly Margulis	3
2	Evaluating Therapeutic Efficacy of the Vascular Disrupting Agent OXi8007 Against Kidney Cancer in Mice 2025 ·Cancers ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Hans J. Hammers, Payal Kapur, (unknown), (unknown), Tianyuan Wang, (unknown), Mary Lynn Trawick, Kevin G. Pinney, Ralph P. Mason	2
3	5 A Phase 1b, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREGTM) in Patients with Advanced or Metastatic Renal Cell Carcinoma, NCT06234605 2024 ·The Oncologist ·Rana R. McKay, (unknown), Pedro C. Barata, Moshe Chaim Ornstein, Neil J. Shah, Hans J. Hammers, Thomas E. Hutson, Michael Chisamore, (unknown), (unknown), Eric S. Lightcap, (unknown), Ben J. Harrison, (unknown), Nandita Bose, (unknown), Robert J. Motzer	1
4	Phase 1/2 study of NGM707, an ILT2/ILT4 dual antagonist antibody, in advanced solid tumors: Interim results from dose-escalation. 2024 ·Journal of Clinical Oncology ·Judy S. Wang, David Sommerhalder, Manish Sharma, William J. Edenfield, Kartik Sehgal, Do‐Youn Oh, Yixing Jiang, Joel Michalski, Jeeyun Lee, Hans J. Hammers, Li‐Yuan Bai, Chih‐Hung Hsu, (unknown), Kefei Zhou, Lisa K. Blum, (unknown), (unknown), Hsiao D. Lieu, Vladimir Hanes, Aung Naing	2
5	Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214 2024 ·Journal for ImmunoTherapy of Cancer ·Charlene Mantia, Opeyemi A. Jegede, Elizabeth R. Plimack, Thomas Powles, Robert J. Motzer, Nizar M. Tannir, Chung‐Han Lee, Yoshihiko Tomita, Martin H. Voss, Toni K. Choueiri, Brian I. Rini, Hans J. Hammers, Bernard Escudier, Laurence Albigès, Lisa Rosenblatt, Michael B. Atkins, Meredith M. Regan, David F. McDermott	6
6	Monovalent and Divalent Designs of Copper Radiotheranostics Targeting Fibroblast Activation Protein in Cancer 2024 ·Cancers ·(unknown), Sashi Debnath, Anjan Bedi, Manish Parashar, (unknown), (unknown), Hans J. Hammers, Xiankai Sun	2
7	Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B) 2023 ·Journal for ImmunoTherapy of Cancer ·Michael B. Atkins, Opeyemi A. Jegede, Naomi B. Haas, David F. McDermott, Mehmet Asım Bilen, Mark N. Stein, Jeffrey A. Sosman, Robert Alter, Elizabeth R. Plimack, Moshe Chaim Ornstein, Michael E. Hurwitz, David Peace, Sabina Signoretti, Thomas Denize, Alessia Cimadamore, Catherine J. Wu, David A. Braun, David J. Einstein, Paul J. Catalano, Hans J. Hammers	19
8	The 5th Kidney Cancer Research Summit: Research Accelerating Cures for Renal Cell Carcinoma in 2023 2023 ·The Oncologist ·Toni K. Choueiri, Sumanta K. Pal, Bryan Lewis, (unknown), (unknown), Hans J. Hammers	2
9	1889P Phase Ib/II study of batiraxcept (BT, AVB-S6-500, an AXL pathway inhibitor) in combination with cabozantinib (cabo) in patients with advanced clear cell renal cell carcinoma (ccRCC) who failed first-line (1L) therapy 2023 ·Annals of Oncology ·Neal Shah, Matthew T. Campbell, Shifeng Mao, Moshe Chaim Ornstein, Naomi B. Haas, Xin Gao, Hans J. Hammers, (unknown), Christopher Hoimes, Arif Hussain, Saby George, Theodore Stewart Gourdin, Ariel Ann Nelson, Hao Yan, (unknown), Gail McIntyre, R. Geller, Martin H. Voss, Brian I. Rini, Kathryn E. Beckermann	0
10	Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma 2022 ·Clinical Genitourinary Cancer ·Jianyi Yin, Roy Elias, Lan Peng, (unknown), (unknown), Alana Christie, Nisa Kubiliun, James Brugarolas, Hans J. Hammers	16
11	Theranostic Small-Molecule Prodrug Conjugates for Targeted Delivery and Controlled Release of Toll-like Receptor 7 Agonists 2022 ·International Journal of Molecular Sciences ·Sashi Debnath, Guiyang Hao, Bing Guan, (unknown), (unknown), Hans J. Hammers, Xiankai Sun	18
12	Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial 2021 ·European Urology Oncology ·Brian I. Rini, Michael B. Atkins, Elizabeth R. Plimack, Denis Soulières, Ray McDermott, Jens Bedke, Sophie Tartas, B. Yа. Alekseev, Bohuslav Melichar, Yaroslav Shparyk, Chihiro Kondoh, (unknown), Lori Wood, Hans J. Hammers, (unknown), Barbara Haber, Erin Jensen, Mei Chen, Thomas Powles	25
13	Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma 2020 ·Journal for ImmunoTherapy of Cancer ·Viral Patel, Roy Elias, (unknown), William Schwartzman, Alana Christie, Qi Cai, Venkat S. Malladi, Payal Kapur, Miguél Vázquez, Renée M. McKay, Iván Pedrosa, Raquibul Hannan, Hans J. Hammers, James Brugarolas	24
14	Summary from the Kidney Cancer Association’s Inaugural Think Thank: Coalition for a Cure 2020 ·Clinical Genitourinary Cancer ·Brian I. Rini, E. Jason Abel, Laurence Albigès, Axel Bex, James Brugarolas, Ronald M. Bukowski, Jonathan Coleman, Charles G. Drake, Robert A. Figlin, Andy Futreal, Hans J. Hammers, Thomas Powles, W. Kimryn Rathmell, Christopher J. Ricketts, Samra Turajlic, Christopher G. Wood, Bradley C. Leibovich	3
15	Summary From the First Kidney Cancer Research Summit, September 12–13, 2019: A Focus on Translational Research 2020 ·JNCI Journal of the National Cancer Institute ·Toni K. Choueiri, Michael B. Atkins, Ziad Bakouny, Maria I. Carlo, Charles G. Drake, Eric Jonasch, Payal Kapur, Bryan Lewis, W. Marston Linehan, Michael J. Mitchell, Sumanta K. Pal, (unknown), (unknown), W. Kimryn Rathmell, Brian I. Rini, Sabina Signoretti, Nizar M. Tannir, Robert G. Uzzo, Christopher G. Wood, Hans J. Hammers	15
16	Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study breakdown → 2017 ·Journal of Clinical Oncology ·Hans J. Hammers, Elizabeth R. Plimack, Jeffrey R. Infante, Brian I. Rini, David F. McDermott, Lionel D. Lewis, Martin H. Voss, Padmanee Sharma, Sumanta K. Pal, Albiruni R. Abdul Razak, Christian Kollmannsberger, Daniel Y.C. Heng, Jennifer L. Spratlin, M. Brent McHenry, Asim Amin	348
17	Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870) 2017 ·Clinical Cancer Research ·Роберто Пили, David I. Quinn, Hans J. Hammers, Paul Monk, Saby George, Tanya B. Dorff, Thomas Olencki, Li Shen, Ashley Orillion, Dominick Lamonica, (unknown), Zsolt Szabó, Alan D. Hutson, Adrienne Groman, Susan M. Perkins, Richard Piekarz, Michael A. Carducci	76
18	Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial breakdown → 2014 ·Journal of Clinical Oncology ·Robert J. Motzer, Brian I. Rini, David F. McDermott, Bruce G. Redman, Timothy M. Kuzel, Michael R. Harrison, Ulka N. Vaishampayan, Harry A. Drabkin, Saby George, Theodore F. Logan, Kim Margolin, Elizabeth R. Plimack, Alexandre Lambert, Ian M. Waxman, Hans J. Hammers	865
19	Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment 2012 ·Cancer Research ·John T. Isaacs, Lizamma Antony, Susan L. Dalrymple, W. Nathaniel Brennen, (unknown), Hans J. Hammers, Michel D. Wissing, Sushant K. Kachhap, Jun Luo, Li Xing, Per Björk, Anders Olsson, (unknown), Tomas Leanderson	89
20	Combination of the VEGF receptor tyrosine kinase sunitinib and the mTOR inhibitor rapamycin leads to tumor regression in the RENCA model 2008 ·Cancer Research ·Hans J. Hammers, (unknown), Li Shen, Michelle A. Rudek, Роберто Пили	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact